I'm finally getting around to beginning to blog notes from and thoughts about the HemOnc Today - Melanoma and Cutaneous Malignancies Conference.
One of the key items talked about and circulated during and after the conference was a table in a presentation entitled Intralesional Therapy For Systemic Disease: Where Will It Fit In? by Dr. Robert Andtbacka, an assistant professor of surgery at the Huntsman Cancer Institute at the University of Utah. As far as I can tell, Dr. Andtbacka has no connection to or relationship with Provectus.
In the table, below, PV-10 compares very favorably to other intralesional therapies:
Dr. Andtbacka's presentation was thorough, reviewing available intralesional therapies and those in development, response rates of and adverse reactions to intralesional therapies, and the role of intralesional therapies in the Stage IV disease state for melanoma. More later...